TLX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX.O) is 207.95, compared to its 5-year average forward P/E of 110.33. For a more detailed relative valuation and DCF analysis to assess Telix Pharmaceuticals Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

110.33

Current PE

207.95

Overvalued PE

185.63

Undervalued PE

35.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

53.59

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

62.95

Undervalued EV/EBITDA

44.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.56

Current PS

0.00

Overvalued PS

7.44

Undervalued PS

3.67

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TLX News & Events

Events Timeline

No data

News

7.0

01-07Globenewswire

Telix Pharmaceuticals Faces Securities Class Action as Stock Plummets 21%

7.0

01-07PRnewswire

Telix Pharmaceuticals Faces Class Action for Securities Fraud Allegations

7.0

01-07Globenewswire

Telix Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements

People Also Watch

Frequently Asked Questions

What is Telix Pharmaceuticals Ltd (TLX) stock price today?

The current price of TLX is 7.5 USD — it has increased 0.54 % in the last trading day.

What is Telix Pharmaceuticals Ltd (TLX)'s business?

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

What is the price predicton of TLX Stock?

Wall Street analysts forecast TLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Telix Pharmaceuticals Ltd (TLX)'s revenue for the last quarter?

Telix Pharmaceuticals Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Telix Pharmaceuticals Ltd (TLX)'s earnings per share (EPS) for the last quarter?

Telix Pharmaceuticals Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Telix Pharmaceuticals Ltd (TLX)'s fundamentals?

The market is revising Upward the revenue expectations for Telix Pharmaceuticals Limited (TLX) for FY2025, with the revenue forecasts being adjusted by 2.85% over the past three months. During the same period, the stock price has changed by -26.76%.

How many employees does Telix Pharmaceuticals Ltd (TLX). have?

Telix Pharmaceuticals Ltd (TLX) has 0 emplpoyees as of January 08 2026.

What is Telix Pharmaceuticals Ltd (TLX) market cap?

Today TLX has the market capitalization of 2.51B USD.